Gilead/Kite’s Tecartus Moves Into Leukemia With Second US Indication
Executive Summary
New indication for second-line-plus acute lymphoblastic leukemia means Tecartus will compete with Novartis’s Kymriah, although the Gilead/Kite product is approved for older patient base.
You may also be interested in...
Kite Wins EMA Recommendation To Market Tecartus For Leukemia Patients
The European Medicines Agency has recommended new uses for six approved products, including the CAR T-cell therapy Tecartus.
ASH Preview: Three Areas To Watch In Hematology-Oncology
Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.
Earlier-Stage Approvals For Tecentriq, Keytruda, Verzenio Underscore Broader Oncology Trends
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker